Satellos Bioscience Inc MSLE 深 沪
等待开盘 02-20 09:30:00 美东时间
11.11
-0.150
-1.33%
华盛通- 最 高11.43
- 今 开11.14
- 成交量 4.61万股
- 最 低 11.11
- 昨 收 11.26
- 总市值 0
- 52周最高 12.14
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 10.725
- 委 比 68.35%
- 总股本 --
- 历史最高 12.14
- 量 比 0.54
- 振 幅 2.84%
- 历史最低 10.725
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Satellos Bioscience Inc. to Present at Major Investor Conferences
Satellos Bioscience Inc. to Present at Major Investor Conferences Satellos Bioscience Inc. will participate in several upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual, February 26, 2026), the TD Cowen 46th Annual Health Care Conferenc
02-17 20:01
BRIEF-Satellos Announces Pricing Of Us$50 Million Public Offering In Canada And The United States
BRIEF-Satellos Announces Pricing Of Us$50 Million Public Offering In Canada And The United States Feb 6 (Reuters) - Satellos Bioscience Inc MSCL.TO : SATELLOS ANNOUNCES PRICING OF US$50 MILLION PUBLIC OFFERING IN CANADA AND THE UNITED STATES SATELLOS BIOSCIENCE INC - COMMON SHARES SOLD AT US$10.10 P
02-06 21:31
Satellos Bioscience Wins FDA and Global Clearance for Phase 2 Duchenne Study
Satellos Bioscience Inc. has received clearance from the U.S. Food and Drug Administration (FDA) and multiple global regulatory agencies to initiate a Phase 2 pediatric clinical trial of its investiga...
2025-12-09 20:01
BRIEF-Satellos Says SAT-3247 Shows Safety And Tolerability In Phase 1 A/B Study
Oct 10 (Reuters) - Satellos Bioscience Inc MSCL.TO: SATELLOS ANNOUNCES NEW DATA FURTHER DEMONSTRATING SAFETY, TOLERABILITY, AND FUNCTIONAL IMPACT OF SAT-3247 IN FIRST-IN-HUMAN TRIAL OF ADULTS WITH DUC...
2025-10-10 21:48
Satellos Bioscience Inc. to Participate in PPMD's Annual Conference in Las Vegas
Satellos Bioscience Inc. will participate in the Parent Project Muscular Dystrophy (PPMD) Annual Conference from June 19-21, 2025, in Las Vegas, Nevada. The company, which focuses on developing new sm...
2025-06-16 19:00
